A. Azaryan

发表

Late Breaking Abstract - Evaluation of the JNK inhibitor, CC-90001, in a phase 1b pulmonary fibrosis trial

B. Bennett, P. Schafer, S. Greenberg, 2017 .

Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

T. Miller, T. Kipps, J. Gabrilove, 2016, Haematologica.

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody®-CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

P. Lugtenburg, M. Hutchings, S. Rule, 2019, Blood.

Purification and characterization of a paired basic residue-specific yeast aspartic protease encoded by the YAP3 gene. Similarity to the mammalian pro-opiomelanocortin-converting enzyme.

Y. Loh, N. Cawley, T. Friedman, 1993, The Journal of biological chemistry.

Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study

E. Hur, J. Kosek, A. Kivitz, 2019, Rheumatology and Therapy.

High-level expression of the prohormones proenkephalin, pro-neuropeptide Y, proopiomelanocortin, and beta-protachykinin for in vitro prohormone processing.

M. Schiller, A. Kohn, M. Lively, 1997, Protein expression and purification.

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

P. Lugtenburg, M. Hutchings, A. Azaryan, 2021, The Lancet.

Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

T. Miller, T. Kipps, J. Gabrilove, 2013 .

Characteristics of YAP3, a new prohormone processing aspartic protease from S. cerevisiae.

Y. Loh, N. Cawley, T. Friedman, 1995, Advances in experimental medicine and biology.